{"schema_version":"secwatch.filing_event.v1","accession":"0001607062-21-000487","form_type":"8-K","ticker":"RGBP","cik":"0001589150","company_name":"Regen BioPharma Inc","filed_at":"2021-11-05T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.174163+00:00","generated_at":"2026-06-28T12:07:34.281367+00:00","sec_items":["8.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Regen Biopharma reduces convertible note principal by $967,830 via equity and cash","bullets":["Satisfied $967,830 of principal and $539,392 in fees/interest through 706M common shares, 23.7M Series A preferred, and $218,529 cash.","Outstanding convertible note principal fell from $2.36M (June 30, 2021) to $1.40M (November 4, 2021).","Total debt reduction of approximately $1.51M includes principal, fees, penalties, and accrued interest."],"urls":{"canonical":"https://secwatch.observer/filing/0001607062-21-000487","json":"https://secwatch.observer/filing/0001607062-21-000487.json","markdown":"https://secwatch.observer/filing/0001607062-21-000487.md","text":"https://secwatch.observer/filing/0001607062-21-000487.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1589150/000160706221000487/0001607062-21-000487-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1589150/000160706221000487/rgbp110521form8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T12:07:34.281367+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}